Suven Pharmaceuticals Ltd. - Research Center
543064 SUVENPHAR Group (A) BSE data
Results
Statement
More
| Mar ' 24 |
Mar ' 23 |
Mar ' 22 |
Mar ' 21 |
Mar ' 20 |
Equity share capital
| 25.46 |
25.46 |
25.46 |
25.46 |
12.73 |
Share application money
Preference share capital
Reserves & surplus
| 2,030.44 |
1,723.92 |
1,495.24 |
1,039.73 |
770.10 |
Secured loans
| 38.58 |
69.16 |
95.57 |
141.23 |
185.29 |
Unsecured loans
Total
| 2,094.47 |
1,818.54 |
1,616.27 |
1,206.41 |
968.12 |
Gross block
| 758.92 |
710.83 |
692.04 |
567.38 |
455.66 |
Less : revaluation reserve
Less : accumulated depreciation
| 235.38 |
198.80 |
157.84 |
126.22 |
98.92 |
Net block
| 523.54 |
512.03 |
534.19 |
441.16 |
356.74 |
Capital work-in-progress
| 179.08 |
164.81 |
29.99 |
96.32 |
101.71 |
Investments
| 1,084.66 |
710.06 |
599.90 |
426.24 |
276.32 |
Current assets, loans & advances
| 453.43 |
571.43 |
640.81 |
395.11 |
376.11 |
Less : current liabilities & provisions
| 146.24 |
139.79 |
188.62 |
152.42 |
142.76 |
Total net current assets
| 307.19 |
431.64 |
452.18 |
242.69 |
233.35 |
Miscellaneous expenses not written
Total
| 2,094.47 |
1,818.54 |
1,616.27 |
1,206.41 |
968.12 |
Book value of unquoted investments
| 317.21 |
710.06 |
599.90 |
426.24 |
276.32 |
Market value of quoted investments
Contingent liabilities
| 56.30 |
190.84 |
29.38 |
47.70 |
78.83 |
Number of equity sharesoutstanding (Lacs)
| 2545.65 |
2545.65 |
2545.65 |
2545.65 |
1272.82 |